The primary goal of the guideline is to improve the quality of care and the outcome in people with type 2 diabetes in low-resource settings. It recommends a set of basic interventions to integrate management of diabetes into primary health care. It will serve as basis for development of simple algor...ithms for use by health care staff in primary care in low-resource settings, to reduce the risk of acute and chronic complications of diabetes. The guideline was developed by a group of external and WHO experts, following the WHO process of guideline development. GRADE methodology was used to assess the quality of evidence and decide the strength of the recommendations.
more
Допомога при інсульті є пріоритетом в Україні. Рівень смертності від інсульту є
вищим, ніж у більшості Європейських країн. За підрахунками в Україні щороку
перено...сить інсульт близько 130 000 людей; у 2020 році показник
внутрішньолікарняної смертності становив 19,76% усіх госпіталізованих з
інсультом пацієнтів; 30–40% усіх пацієнтів помирали протягом першого місяця
після перенесення інсульту; в цілому інсульт був причиною 13% усіх смертей в
Україні.
more
The World Health Organization invites clinicians and patients to collect information on COVID-19 in a systematic way and contribute clinical data to the WHO Clinical Platform to expand our knowledge on Post-COVID-19 condition, and support patient care and public health interventions.
WHO’s Post... COVID case report form (CRF) has been designed to report standardized clinical data from individuals after hospital discharge or after the acute illness to examine the medium- and long-term consequences of COVID-19. The forms will be available in multiple languages.
more
Q1: In individuals with psychotic disorders (including schizophrenia), are antipsychotic drugs safe and effective?
This is a guide for healthcare workers involved in patient care activities in a healthcare setting. It aims to show the type of personal protective equipment or PPE needed to correctly protect oneself. Based on the current available evidence, the WHO recommended PPE for the care of COVID patients ar...e CONTACT and DROPLET precautions, with the exception of aerosol producing procedures, which require CONTACT and AIRBORNE (hence, a respirator mask such as N95, FFP2, FFP3). Keeping in mind, PPE is part of a larger infection prevention and control bundle of measures and should be implemented as part of a multimodal strategy of management of COVID-19 patients. Only clinical staff who are trained and competent in the use of PPE should be allowed to enter the patient’s room.
This course is also available in the following languages:
العربية -македонски - 中文 - Shqip - français - ภาษาไทย - Português - Español - Nederlands - Tetun
more
This training is part of the national Rapid Response Team Training package, adapted to take into account specific issues pertaining to the COVID-19 outbreak. Several technical aspects presented here were developed and posted on different WHO platforms and for larger / different audiences. In this pa...ckage, we have regrouped the essential elements that you, as a member of the national RRT, may wish to take into account as you perform COVD-19 related activities
The objectives of this online learning package is to provide National Rapid Response Teams members with the key knowledge and tools needed to early detect and effectively respond to a Covid-19 outbreak.
more
Orientations provisoires, 27 mai 2021
31 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Countries around the world are rolling ou...t COVID-19 vaccines, and a key topic of interest is their safety. Vaccine safety is one of WHO’s highest priorities, and we’re working closely with national authorities to develop and implement standards to ensure that COVID-19 vaccines are safe and effective.
more
Report of the 23rd WHO Expert Committee on the selection and use of essential medicines
This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc)....
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and formulation on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
more
Dos & Don'ts for Volunteers: How to support refugees in a responsible and ethical manner
Readily access selected guidelines, reports and other knowledge resources to enhance evidence-informed, multisectoral, and multistakeholder initiatives in NCD prevention and control – curated by WHO's Global NCD Platform and supported by GCM Participants.
The BeatChagas platform is a tool developed by the Technical Group of Information, Education, and Communication (IEC) for Chagas Disease (TG6-IEC Chagas), part of the Chagas Disease Control Program by the World Health Organization (WHO). The purpose of this platform is to share information about the... TG6-IEC group’s activities.
more
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above publication and has been prepared to specifically assist national medicines regulatory authorities to... understand the nature and extent of oxytocin quality issues and to provide key technical information and quality requirements for oxytocin products in dossier assessments. Furthermore, this document also presents recommendations on other regulatory actions needed to ensure that only quality-assured oxytocin products are authorized and made available to women.
more